Mode
Text Size
Log in / Sign up

Rapamycin therapy reduced infections and lymph node size in a female child with APDS1Neck Mass Was Not Cancer, It Was This Rare Condition

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider rapamycin as a potential therapy option for APDS1, but recognize that evidence is limited to a single case report.

A single female adopted child was diagnosed with Activated phosphoinositide 3-kinase delta syndrome type I (APDS1) following initial misdiagnosis as lymphoma, cystic fibrosis, or primary ciliary dyskinesia. Genetic testing confirmed the diagnosis via a PIK3CD mutation. The patient was treated with rapamycin-targeted therapy in conjunction with compound sulfamethoxazole within a hospital setting.

Treatment resulted in a significant reduction in the frequency of pulmonary infection episodes. Additionally, the size of enlarged lymph nodes in the neck decreased, and overall control of the condition was deemed effective. No specific numerical data, p-values, or confidence intervals were reported for these outcomes.

Regarding safety, adverse events, serious adverse events, discontinuations, and tolerability were not reported in this case report. The patient remained on the regimen during subsequent follow-up without documented interruptions or adverse reactions.

Limitations of this evidence include the small sample size of one patient and the lack of a control group. Consequently, the findings cannot be generalized to the broader population of patients with APDS1. This report aims to enhance clinicians' understanding of this rare primary immunodeficiency disorder rather than to define standard care.

Imagine a child coughing up yellow mucus for years.

Doctors thought it was cystic fibrosis or a common infection.

Then a lump appeared on her neck.

Everyone guessed it was cancer.

But the real problem was hidden inside her genes.

Recurrent lung infections are exhausting for families.

This young girl needed hospital visits two or three times every year.

Standard antibiotics often failed to clear the infection.

She also suffered from sinusitis and breast cysts.

Doctors struggled to find a single cause.

Many rare immune disorders go undiagnosed for years.

Patients suffer while waiting for the right answer.

The surprising shift

For years, doctors suspected cystic fibrosis.

They also considered primary ciliary dyskinesia.

These conditions cause lung mucus to build up.

But this patient had a different issue.

The neck mass looked like lymphoma under the microscope.

Lymphoma is a type of blood cancer.

The first test said it was cancer.

Then the second test said it was not.

But here is the twist.

The real diagnosis was a genetic immune disorder.

What scientists didn't expect

Our bodies have special cells to fight germs.

These cells act like security guards at a gate.

In this case, the guards were stuck in the door.

They could not let bad germs in.

But they also could not let good things pass.

This blocked the immune system from working right.

It caused infections and strange lumps to grow.

Think of your immune system as a busy highway.

Traffic needs to flow smoothly to reach its destination.

In this condition, a traffic jam forms at the start.

A specific protein called PI3K delta gets stuck on.

It sends too many signals to the immune cells.

These cells get confused and stop working well.

The result is frequent infections and swollen glands.

The gene responsible is called PIK3CD.

A small change in this gene breaks the system.

This report shares one specific patient story.

The girl was adopted and had health issues early.

She started having lung problems at six months old.

Doctors tested her blood and took pictures of her neck.

They found a mass that looked scary.

Genetic testing finally gave the real answer.

The test showed a mutation in the PIK3CD gene.

This confirmed the diagnosis of APDS1.

The most important result was the treatment success.

Doctors gave her a drug called rapamycin.

This drug helps reset the stuck traffic signal.

She also took medicine to prevent infections.

The results were clear and positive.

Her lung infections happened much less often.

The swollen neck lump got smaller and disappeared.

Her overall health improved significantly over time.

This doesn't mean this treatment is available yet.

This case fits into a growing group of rare diseases.

Scientists are learning more about immune system glitches.

These disorders are often missed because they are so rare.

Doctors need to know the signs to look for.

Early genetic testing can save years of confusion.

Knowing the exact cause helps doctors pick the right drug.

If your child has frequent lung infections, talk to a doctor.

Ask if a genetic test is an option.

Do not assume a neck lump is always cancer.

Sometimes the answer lies in a blood test.

Early diagnosis can change the entire treatment plan.

Talk to a specialist if standard treatments fail.

This story is about one specific patient.

It is a case report, not a huge study.

We do not know if this works for everyone.

The drug used is for specific genetic mutations.

Not every hospital has this test or drug.

More research is needed to prove it works broadly.

Scientists will study more patients with this gene mutation.

They hope to find better ways to fix the traffic jam.

New drugs might become available in the future.

For now, genetic testing is the key tool.

It helps doctors see the problem clearly.

Families should ask about genetic counseling if infections are severe.

Understanding the cause brings hope and better care.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
This article presents a case characterized by recurrent pulmonary infections and a poor therapeutic response. Initially, cystic fibrosis (CF) or Primary ciliary dyskinesia was suspected; however, the patient subsequently sought medical attention for a neck mass. The mass was initially misdiagnosed as lymphoma, but a comprehensive examination and assessment ultimately confirmed the diagnosis of activated phosphoinositide 3-kinase delta syndrome type I(APDS1). Through the patient’s tortuous diagnostic journey, this report aims to enhance clinicians’ understanding of this rare primary immunodeficiency disorder. Clinical picture: The patient is a female adopted child who has experienced recurrent lung infections since the age of 6 months. On average, she has required hospitalization 2–3 times annually, with conventional anti-infection treatments proving less effective. Throughout her illness, she was admitted to another hospital for sinusitis and breast cysts, although the specifics of her treatment remain unclear. Subsequently, she presented to our hospital with symptoms of coughing, yellow sputum, and hemoptysis. During her hospitalization, a new neck mass was identified. Key inspection: Imaging assessment revealed a chest CT indicating pulmonary infection and bronchiectasis with mucus plug formation. Neck CT and MRI suggested a potential diagnosis of lymphoma. Pathogen testing through nucleic acid analysis for respiratory pathogens yielded positive results for mycoplasma and adenovirus influenzae. Laboratory and abdominal ultrasound did not identify any abnormalities in the pancreas. A peripheral blood immunological assessment demonstrated significantly diminished cellular and humoral immune functions. Following the resection of the cervical mass, the initial pathological diagnosis was lymphoma; however, tests for T-cell receptor (TCR) and immunoglobulin (IG) gene rearrangements returned negative results. After a multidisciplinary consultation and subsequent pathological re-examination, the diagnosis was revised to infectious mononucleosis. Genetic testing revealed a heterozygous mutation in the PIK3CD gene. Final diagnosis: Activated phosphatidylinositol 3-kinase δ syndrome type I (APDS1). Treatment and prognosis: Following diagnosis, the child was administered rapamycin-targeted therapy in conjunction with compound sulfamethoxazole to prevent infections, with regular monitoring of rapamycin blood concentrations. Subsequent follow-up indicated a significant reduction in the frequency of pulmonary infection episodes, a decrease in the size of the enlarged lymph nodes in the neck, and effective control of the condition.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.